RxDoctor Payments Data

Marcia Genta, MD

Rheumatology · Dallas, TXNPI 1134233976

Payments from drug & device makers

$7,746in general payments, 2019–2025

Across 371 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • Pfizer$827
  • AstraZeneca$556
  • Johnson & Johnson$553
  • UCB, Inc.$476
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$7,722100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,746 in reported general payments places this provider in the 55th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$127,009
Medicare patients
103
Services billed
11,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab144$1,131,692
Enbrel SureclickEtanercept117$961,920
Orencia ClickjectAbatacept43$233,200
Cimzia (2 Pack)Certolizumab Pegol24$156,604
Cosentyx Sensoready PenSecukinumab13$106,800
OtezlaApremilast14$63,791
KevzaraSarilumab12$53,681
RasuvoMethotrexate/Pf28$23,236
Hydroxychloroquine Sulfate448$13,280
MethotrexateMethotrexate Sodium565$10,269
Pilocarpine Hcl16$1,489
Folic Acid195$1,342
Sulfasalazine24$736
Allopurinol65$609
Tramadol Hcl92$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$476$156,60424 claims
AmgenOtezla$1,480$63,79114 claims
SanofiKevzara$110$53,68112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →